The Lanosterol 14 Alpha Demethylase pipeline drugs market research report outlays comprehensive information on the Lanosterol 14 Alpha Demethylase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Lanosterol 14 Alpha Demethylase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Ophthalmology, Oncology, and Respiratory which include the indications Aspergillosis, Fungal Infections, Age Related Macular Degeneration, Eye Infections, Oncology, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), and Asthma. It also reviews key players involved in Lanosterol 14 Alpha Demethylase targeted therapeutics development with respective active and dormant or discontinued products.
The Lanosterol 14 Alpha Demethylase pipeline targets constitutes close to 28 molecules. Out of which, approximately 22 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/ CTA Filed, and Preclinical stages are 3, 6, 5, 1, 1, 1, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 3 molecule.
Lanosterol 14 Alpha Demethylase overview
Lanosterol 14 alpha-demethylase (LDM) is a cytochrome P450 enzyme that catalyzes the 14 alpha-demethylation of lanosterol. Lanosterol is the first step in sterol formation. LDM can convert lanosterol to follicular fluid meiosis activating factor (FF-MAF), a sterol intermediate that activates meiosis in gametes.
For a complete picture of Lanosterol 14 Alpha Demethylase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
